Here, we found that the doxorubicin-sensitive myeloma cell line showed significant DNA damage and up-regulated expression of genes associated with the IFN response, which was not observed in drug-insensitive cell lines. The gene discussed is IFNA1; the disease is plasma cell myeloma.